๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the register
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
รˆn dosis intravenรธs penicillin som tillรฆg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillรฆr phlegmone og peritonsillรฆr absces โ€“ et randomiseret, dobbeltblindet, placebo-kontrolleret studie
2026-526903-31-00Tonsillitis
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
21/08/2026
Phase III
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigatorโ€™s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritโ€ฆ
K-Group Beta Inc.
Neoplasms
Germany, Spain, Italy, Belgium, Poland, France, Ireland
21/08/2026
Phase I
A study to see how safe a new medicine (NNC0705-0002) is in healthy people
2026-526205-15-00Cardiometabolic
Novo Nordisk A/S
Not possible to specify
Netherlands
21/08/2026
Phase I
A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
2025-524555-31-00Recurrent Glioblastoma
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Nervous System Diseases
Netherlands
21/08/2026
Phase II
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
2026-525418-67-00Multiple Myeloma
Instytut Hematologii I Transfuzjologii
Hemic and Lymphatic Diseases
Poland
21/08/2026
Phase III
A 52-week multicenter, randomized, parallel-group trial in overweight people investigating lifestyle changes, mushroom supplementation and bupropion to reduce adiposity and cardiometabolic risk
2026-527136-13-00Overweight or class I obesity (BMI 25.0โ€“34.9 kg/mยฒ), with oโ€ฆ
Uppsala University
Cardiovascular Diseases
Sweden
21/08/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With ฮฑ- or ฮฒ-Transfusion-Dependent Thalassemia (ENERGIZEKids-T)
2025-524707-71-00Transfusion-Dependent Alpha- or Beta-Thalassemia
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, Greece
20/08/2026
Phase III
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
2025-523252-31-00High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals Inc.
Neoplasms
Italy, Spain, Poland, France, Norway, Greece, Germany
20/08/2026
Phase I
Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL "Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study" A prospective non-randomized multicenter phase I study
2024-520342-28-00relapsed/ refractory Primary central nervous system lymphomโ€ฆ
Medizinische Universitaet Innsbruck
Nervous System Diseases
Germany, Austria
20/08/2026
Phase I
Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity
2026-525397-19-00Recurrent Glioblastoma
Heinrich-Heine-Universitaet Duesseldorf
Neoplasms
Germany
20/08/2026
Phase III
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
2026-525296-60-00Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
Eye Diseases
Belgium, France, Spain, Italy, Germany
20/08/2026
Phase I/II
Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA
2026-525463-40-00osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like โ€ฆ
Les Hopitaux Universitaires De Strasbourg
Neoplasms
France
20/08/2026
Phase IV
Effects of Menopausal Hormone Therapy on QTc in Genetically Confirmed Long QT Syndrome: A Prospective Randomized Sequential Crossover Study with Long-Term Observational Follow-Up (LQTS-HER)
2026-526442-28-00Long QT syndrome
Oslo Universitetssykehus HF
Cardiovascular Diseases
Norway
20/08/2026
Phase I/II
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON)
2025-524171-22-00Solid Tumors
AstraZeneca AB
Neoplasms
Spain
20/08/2026
Phase IV
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2026-526068-19-00Transthyretin Amyloidosis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Spain, Denmark
20/08/2026
Phase III
Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) and Pleurectomy in the local treatment of pleural tumors. A Prospective Randomized Study The Tic-Tac Trial
2026-526109-13-00malignant pleural effusion
Universita' Degli Studi Di Torino
Neoplasms
Italy
20/08/2026
Phase II
J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D
2025-524973-17-00Irritable Bowel Syndrome Diarrhea
Eli Lilly & Co.
Digestive System Diseases
Germany, Poland, Spain, Belgium
20/08/2026
Phase II
Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)
2026-525826-39-00Post-Traumatic Stress Disorder
Centre Hospitalier Regional Universitaire De Tours
Mental Disorders
France
19/08/2026
Phase I
A clinical trial of MK-8210 in healthy participants (MK-8210-001)
2026-527022-13-00HIV-1 (Human Immunodeficiency Virus Type 1)
Merck Sharp & Dohme LLC
Virus Diseases
Belgium
19/08/2026
Phase III
JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)
2025-522310-24-00Depressive Disorder, Major
Eli Lilly & Co.
Mental Disorders
Poland, Greece, Spain, Germany
19/08/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
2026-526777-42-00Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics Inc.
Neoplasms
Spain
19/08/2026
Phase I/II
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
2025-525036-34-00Solid Tumours
Terremoto Biosciences Inc.
Neoplasms
Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland
18/08/2026
Phase III
Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)
2025-525159-20-00myocardial infarction
Montreal Heart Institute
Cardiovascular Diseases
France
18/08/2026
Phase III
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524756-54-00Ocular Myasthenia Gravis
UCB Biopharma
Immune System Diseases
Hungary, Greece, Italy, Spain, Germany, Poland, France
18/08/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants with CAD
2026-525901-10-00Coronary artery disease
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Sweden, Poland
18/08/2026
Rows per page Showing 176–200 of 2500
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.